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Available online 8 January 2016Introduction: Despite excellent ﬁrst year outcomes in kidney transplantation, there remain signiﬁcant long-term
complications related to new-onset diabetes after transplantation (NODAT). The purpose of this studywas to val-
idate the ﬁndings of previous investigations of candidate gene variants in patients undergoing a protocolised,
contemporary immunosuppression regimen, using detailed serial biochemical testing to identify NODAT
development.
Methods: One hundred twelve live and deceased donor renal transplant recipients were prospectively followed-
up for NODAT onset, biochemical testing at days 7, 90, and 365 after transplantation. Sixty-eight patients were
included after exclusion for non-white ethnicity and pre-transplant diabetes. Literature review to identify
candidate gene variants was undertaken as described previously.
Results: Over 25% of patients developed NODAT. In an adjusted model for age, sex, BMI, and BMI change over
12 months, ﬁve out of the studied 37 single nucleotide polymorphisms (SNPs) were signiﬁcantly associated
with NODAT: rs16936667:PRDM14 OR 10.57;95% CI 1.8–63.0;p = 0.01, rs1801282:PPARG OR 8.5; 95% CI 1.4–
52.7; p = 0.02, rs8192678:PPARGC1A OR 0.26; 95% CI 0.08–0.91; p = 0.03, rs2144908:HNF4A OR 7.0; 95% CI
1.1–45.0;p = 0.04 and rs2340721:ATF6 OR 0.21; 95%CI 0.04–1.0; p = 0.05.
Conclusion: This study represents a replication study of candidate SNPs associated with developing NODAT and
implicates mTOR as the central regulator via altered insulin sensitivity, pancreatic β cell, and mitochondrial
survival and dysfunction as evidenced by the ﬁve SNPs.
General signiﬁcance:
1) Highlights the importance of careful biochemical phenotyping with oral glucose tolerance tests to diagnose
NODAT in reducing time to diagnosis and missed cases.
2) This alters potential genotype:phenotype association.
3) The replication study generates the hypothesis that mTOR signalling pathway may be involved in NODAT
development.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
New-onset diabetes after transplantation
single nucleotide polymorphisms
mTORBMI, Body mass index; GWAS,
te antigen; HNF4, Hepatocyte
n; NODAT, New-onset diabetes
GC1α, Peroxisome proliferator-
xisome proliferator-activated re-
ingle nucleotide polymorphism.
y and Kidney Transplantation,
TH, USA.
. This is an open access article under1. Introduction
Despite excellent ﬁrst-year outcomes in kidney transplantation,
there remain signiﬁcant long-term complications of premature graft
loss, morbidity, and mortality related to infection and cardiovascular
disease. New-onset diabetes after transplantation (NODAT) is the
major form of post-transplant hyperglycaemia that is associated with
such complications. Thus research has focussed on preventative mea-
sures to post-transplant hyperglycaemia development, identiﬁcation
of those at risk in a timely manner, and investigating molecular
pathways to its development.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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offers such a strategy. A number of previous studies have investigated
speciﬁc candidate gene variants, usually on the basis of prior evidence
of association with type 2 diabetes in non-transplanted individuals.
While some such SNPs have shown an association with NODAT, little
attempt has been made to replicate ﬁndings in independent cohorts.
More recently, the ﬁrst genome-wide association study (GWAS) in the
ﬁeld has been reported [1]. In this study, NODAT was deﬁned as the
use of oral hypoglycaemics or insulin over a 12 year follow-up period,
with the median time of NODAT onset of 100 months, and recent
work highlights the growing momentum to use biochemical testing
when identifying post-transplant hyperglycaemia [2,3]. It is also worth
noting that 25% of patients in this GWAS study were treated with a
calcineurin inhibitor-free maintenance regimen. Our group has re-
cently shown the use of biochemical deﬁnitions of post-transplant
hyperglycaemia can alter the clinical phenotype-to-genotype associa-
tion to such an effect that none of the eightβ ‘glucotoxic’ SNPs identiﬁed
in the GWAS were associated with NODAT in our cohort [4].
The purpose of this study was to validate the ﬁndings of the GWAS
and other candidate NODAT SNPs investigated in the Belfast study [1],
but in a prospective study of patients undergoing a protocolised,
contemporary immunosuppression regimen, and using detailed serial
biochemical testing to identify the development of NODAT.
2. Patients and methods
From 2009 to 2012, 112 live and deceased donor renal transplant
recipients were prospectively followed-up over a 12 month period in
a single-centre adult tertiary centre at Queen Elizabeth Hospital
Birmingham, United Kingdom. To exclude pre-existing diabetes,
patients underwent glucose testing (after a minimum of 8 h fasting)
immediately prior to transplantation and excluded if ≥6.1 mmol/l
or HbA1c ≥6.5% (48 mmol/mol). In addition, live donor recipients
underwent oral glucose tolerance testing (OGTT) with a standard 75 g
glucose load within a week prior to transplantation. Following trans-
plantation, OGTTs were then performed at 7 days, and then 3 months
and 12 months in all patients except those who developed clinically
manifest hyperglycaemia requiring treatment. NODAT was diagnosed
if a) fasting glucose ≥7 mmol/l or 2 h OGTT was ≥11.1 mmol/l from
day 7 onwards and persisted at the 3 month timepoint, b) HbA1c
≥6.5% (48mmol/mol) from3months onwards, or c) requirement for in-
stitution of therapy for NODAT in which case OGTT was not undertaken
(fasting clinic glucose was ≥7 mmol/l in all such patients). Exclusion
criteria of pre-transplant diabetes and the requirement for exclusion
of non-white patients to avoid population stratiﬁcation in a genetic in-
vestigation such as this resulted in 68 patients being prospectively
followed.
All patients received an identical immunosuppression regimen
consisting of anti-CD25 monoclonal antibody induction followed by
maintenance tacrolimus (target per-dose trough levels 5–8 ng/ml by
liquid chromatography with tandemmass spectrometry), mycopheno-
late mofetil (2 g daily dose), and prednisolone (20 mg/day initially
weaning to 5 mg/day by 3 months, and then continued).
Literature review to identify candidate genevariantswas undertaken
as described previously [1]. The eight β ‘glucotoxic’ SNPs that have been
previously been investigated for NODAT in this cohort were excluded
[4]. Genotyping were performed using Sequenom iPLEX technology.
The study received approval from the local research ethics committee
(NRES West Midlands Black Country 08/H1204/103) prior to com-
mencement and was conducted in accordance with the Declarations of
Helsinki and Istanbul with patient written consent.
2.1. Statistical analysis
Data are shown as median (1st and 3rd quartiles) if not normally
distributed or mean (±standard deviation) if normally distributed.Baseline demographics were assessed using Mann–Whitney U (non-
parametric data) or Student t test if normally distributed for continuous
data, and Fisher exact testing for categorical data as appropriate using
SPSS software, version 20 (SPSS Inc., Chicago, Illinois) for analysis.
Genotype distributions were assessed for concordance with Hardy–
Weinberg equilibrium using a χ2 goodness-of-ﬁt test with a type 1
error rate set at 5% analysed using PLINK [5]. Genotype to phenotype as-
sociations and event analyses were conducted using logistic regression
with the development of NODAT at any time during the ﬁrst 12months
post-transplantation as the end measure of interest (time-to-event
analysis was not undertaken due to only 2 post-transplant timepoints).
Univariate genotype:phenotype relationships and then the relationship
in a multivariate model fully adjusted for age, sex, baseline body mass
index (BMI), and change in BMI over 12 months from transplantation
(no selection process) were calculated using PLINK [5].
3. Results
Demographics of the cohort are shown in Table 1. The cohort was
aged 45 years (±15), human leucocyte antigen (HLA) mismatched
2.41 (±1.43), body mass index increase of 1.0 (±2.2) with 68% under-
going live kidney transplantation. Eighteen patients (26.5%) were diag-
nosedwithNODAT, ofwhom11patients (61.1%)were diagnosed on the
basis of the result of OGTT testing alone. Patients developing NODAT
were older and displayed greater changes in BMI over the ﬁrst year of
post-transplantation (p b 0.05 for both). There were no signiﬁcant
differences between patients developing and not developing NODAT
for age, HLA mismatch, rejection episodes, overall steroid dose used
per day, tacrolimus levels, or presence of adult polycystic kidney disease
(p N 0.05 for all). No patients had a prevalent or incident hepatitis
C virus infection.
Out of the remaining 42 candidate SNPs that were identiﬁed by liter-
ature review [1], 37 were successfully genotyped (rs1800961 [HNFA],
rs2069763 [IL-2], rs2265917 [SHPRH], rs6903252 [intergenic], and
rs7903146 [TCF7L2] were unavailable as they were not amenable to
the Sequenom iPLEX genotype bundle designs). The genotype success
rate for the 37 SNPs was N99%. Six SNPs (rs10117679 [GRIN3A],
rs1016429 [GRIN3A], rs12255372 [TCF7L2], rs17657199 [NDST1],
rs2070874 [IL-4], rs2240747 [ZNRF4]) demonstrated deviation from
Hardy–Weinberg equilibrium (p b 0.05).
In the adjusted logistic regressionmodel, ﬁve SNPswere signiﬁcantly
associated with NODAT: rs16936667 [PRDM14: OR 10.57; 95% CI 1.8–
63.0; p = 0.01], rs1801282 [PPARG: OR 8.5; 95% CI 1.4–52.7; p =
0.02], rs8192678 [PPARGC1A: OR 0.26; 95% CI 0.08–0.91; p = 0.03],
rs2144908 [HNF4A: OR 7.0; 95% CI 1.1–45.0; p = 0.04], and rs2340721
[ATF6: OR 0.21; 95% CI 0.04–1.0; p = 0.05] (Table 2).
4. Discussion
This study identiﬁes SNP variants in common genes which are
associatedwith the development of NODAT following kidney transplan-
tation, thereby hypothesis generating to our understanding of mecha-
nisms involved (discussed below) and the potential for risk-stratifying
patients pre-transplantation. Some of the features of the study are
relevant and worth noting in the context of its ﬁndings. Firstly, all
patients underwent screening for diabetes prior to transplantation,
and so the episodes of diabetes following transplantation were truly
‘new onset’ rather than pre-transplant diabetes which was picked up
post-transplantation. Indeed, for the live donor recipients in the study,
OGTTs were also undertaken to exclude pre-transplant diabetes. For
the diagnosis of diabetes following transplantation, OGTTs were under-
taken at serial timepoints in a carefully phenotyped prospective cohort,
and sowe believe that this study is particularly sensitive to the develop-
ment of NODAT. Interestingly, the majority of patients were only diag-
nosed as a result of the OGTTs conducted speciﬁcally and additionally
as part of this research study and would have been missed (or the
Table 1
Demographics of the study cohort.
Characteristic NODAT Non-NODAT All p value
Number of patients (%) 18 (26) 50 (74) 68
Age (years) 54 (±12) 41 (±15) 45 (±15) 0.002
Female (%) 8 (44) 20 (40) 28 (41) 0.785
Body mass index (kg/m2) 27.5 (±4.9) 26.3 (±4.8) 26.6 (±4.8) 0.375
Body mass index change (kg/m2) −0.5 (±2.5) 1.5 (±1.9) 1.0 (±2.2) 0.002
Polycystic kidney disease (%) 3 (17) 7 (14) 10 (15) 0.717
Transplant type, live (%) 13 (72.2) 33 (66) 46 (67.6) 0.775
Human leucocyte antigen mismatch 2.82 (±1.59) 2.45 (±1.36) 2.56 (±1.43) 0.371
Total rejection episodes 0.39 (±0.61) 0.25 (±0.64) 0.29 (±0.63) 0.179
1st month rejection episodes 0.11 (±0.32) 0.13 (±0.33) 0.12 (±0.33) 1.000
Prednisolone dose (mg/day) 9.0 (6.3–9.7) 6.3 (6.3–9.3) 6.3 (6.3–9.7) 0.120
FK level (micrograms/l) 8.8 (±1.5) 8.1 (±1.3) 8.3 (±1.4) 0.107
Bold values indicate signiﬁcance at p value ≤ 0.05.
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inclusion of only white patients (self-reported) does limit generali-
sation to other ethnicities, it does nevertheless make the study's
ﬁndings more robust by limiting (albeit not fully excluding) the con-
founding effect of population stratiﬁcation. Finally, the identiﬁed
SNPs have been previously recognised as risk factors for diabetes
and also for NODAT, and the current study therefore replicates
these ﬁndings. As such, the p values have not been corrected for multi-
ple comparisons. At 5% risk of false positives in the 37 SNPswould result
in approximately 2 false positives assuming that the SNPs were inde-
pendent of each other, yet, in view of the potential inter-relationshipTable 2
Univariate (p value) and multivariate analysis (p value adj) of the candidate single nucleotide
SNP Gene Location Minor allele
rs16936667 PRDM14 8:70975726 G
rs1801282 PPARG 3:12393125 G
rs8192678 PPARGC1A 4:23815662 A
rs2144908 HNF4A 20:42985717 A
rs2340721 ATF6 1:161849385 A
rs5219 KCNJ11 11:17409572 T
rs10899444 SHANK2 11:70606500 G
rs1025689 IL-17RB 3:53883722 G
rs1124053 IL-17E 14:22914819 T
rs2265477 SHPRH 6:146212338 C
rs6793265 ITPR1 3:4735533 T
rs7145618 PPP2R5C 14:102329098 C
rs1783606 SHANK2 11:70576651 A
rs2265919 SHPRH 6:146221753 G
rs3212574 ITGA2 5:52366779 A
rs2107538 CCL5 17:34207780 T
rs2240747 ZNRF4 19:5456930 C
rs17657199 NDST1 5:149950246 T
rs3817655 CCL5 17:34199641 A
rs4819554 IL-17RA 22:17565035 G
rs341497 DIAPH3 13:60429001 C
rs1800795 IL-6 7:22766645 C
rs2280789 CCL5 17:34207003 C
rs1799854 ABCC8 11:17448704 T
rs1016429 GRIN3A 9:104402364 C
rs2069762 IL-2 4:123377980 G
rs1494558 IL-7R 5:35861068 A
rs2172749 IL-7R 5:35855264 C
rs1043261 IL-17RB 3:53899276 T
rs1044498 ENPP1 6:132172368 C
rs2070874 IL-4 5:132009710 T
rs10117679 GRIN3A 9:104378479 T
rs1169288 HNF1A 12:121416650 G
rs13266634 SLC30A8 8:118184783 T
rs12255372 TCF7L2 10:114808902 T
rs1871184 ITGA1 5:52234323 T
rs17722392 KIDINS220 2:8940154 C
Key: SNP: single nucleotide polymorphism,MAF:minor allele frequency, p value adj: p value adjuste
Bold values indicate signiﬁcance at p value ≤ 0.05.(discussed below) of the SNPs, the actual number of false positives is
likely to be lower.
The potential detrimental effects of hyperglycaemia on pancreatic
human β cells resulting in reduced proliferation and increased apopto-
sis after 2 days and loss of secretory function after 4 days have been
shown in vitro which is reﬂected in the time to NODAT onset in this
study [6,7]. The ﬁve reported SNPs associated with NODAT in this
study mirror the above mechanisms, and fall into three main interrelat-
ed categories, namely β cell apoptosis with reduction in cell mass, insu-
lin sensitivity/release, and mitochondrial dysfunction (Fig. 1). The
mammalian target of rapamycin (mTOR) is a member of the phospho-polymorphisms for the development of new-onset diabetes after transplantation.
MAF p value p value adj Odds ratio (95% CI)
0.16 0.03 0.01 10.6 (1.8–63.0)
0.1 0.12 0.02 8.5 (1.4–52.7)
0.34 0.17 0.03 0.26 (0.08–0.91)
0.18 0.05 0.04 7.0 (1.1–45.0)
0.3 0.006 0.05 0.21 (0.04–1.0)
0.34 0.08 0.12 2.7 (0.77–9.8)
0.15 0.77 0.15 0.32 (0.07–1.5)
0.44 0.14 0.15 0.45 (0.15–1.34)
0.23 0.05 0.16 2.7 (0.68–10.3)
0.46 0.54 0.17 0.45 (0.14–1.4)
0.13 0.22 0.23 2.2 (0.60–8.4)
0.07 0.64 0.25 3.1 (0.44–21.5)
0.14 0.99 0.26 0.42 (0.09–1.9)
0.44 0.74 0.29 0.54 (0.18–1.7)
0.23 0.94 0.30 2.1 (0.50–9.2)
0.18 0.07 0.34 2.1 (0.46–9.5)
0.21 0.86 0.37 2.0 (0.45–8.7)
0.03 0.37 0.41 2.5 (0.28–23.3)
0.18 0.12 0.48 1.8 (0.37–8.5)
0.12 0.62 0.49 1.7 (0.38–7.9)
0.06 0.45 0.49 2.0 (0.28–14.1)
0.43 0.90 0.53 0.72 (0.26–2.0)
0.13 0.14 0.59 1.7 (0.26–10.7)
0.4 0.51 0.60 0.75 (0.25–2.2)
0.1 0.41 0.64 1.6 (0.24–10.0)
0.25 0.21 0.66 1.3 (0.39–4.4)
0.35 0.79 0.70 1.2 (0.46–3.2)
0.35 0.79 0.70 1.2 (0.46–3.2)
0.11 0.23 0.71 0.73 (0.14–3.8)
0.14 0.21 0.74 0.80 (0.21–3.1)
0.17 0.60 0.78 0.82 (0.21–3.3)
0.06 0.44 0.81 1.4 (0.1–18.3)
0.36 0.96 0.82 1.1 (0.35–3.8)
0.38 0.53 0.84 0.89 (0.30–2.7)
0.28 0.94 0.91 1.1 (0.41–2.7)
0.13 0.14 0.92 1.1 (0.16–7.4)
0.05 0.44 0.93 1.1 (0.09–13.8)
d for age, sex, bodymass index at baseline and change after 12months, CI: conﬁdence interval.
Fig. 1. Schematic of how the signiﬁcant candidate genes may lead to new-onset diabetes after transplantation development, with mTOR being the central regulator to this.
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the regulation of these SNPs.
It regulates peroxisome proliferator-activated receptor gamma
co-activator 1 alpha (PGC1α – PPARGC1α rs8192678) and peroxisome
proliferator-activated receptor gamma (PPARy – PPARG rs1801282) sig-
nalling to promote cell growth, proliferation, metabolism, and survival;
both these SNPs have been associated with type II diabetes previously
[8,9]. mTOR enhances the activity of these transcription factors PPARy
and PGC1α by the regulation of lipid synthesis, thus acts as a key sensor
formitochondrial and B cell nutrient status via leucine and its regulation
of AMP-activated protein kinase inhibiting secretion of insulin, control-
ling mitochondrial oxidative metabolism, and biogenesis through
transcription PGC1α physical interaction with yin-yang 1 [10,11]. mTOR
regulates the transcription regulator, PR domain zinc protein 14
(PRDM14 rs16936667),which interacts directlywith the chromatin regu-
lator polycomb repressive complex 2 to exert its effects via trimethylation
of histone H3 lysine27 and enhancer of zeste homolog 2 to regulate β cell
proliferation, cell mass, and apoptosis [12–14]. This SNP was associated
with NODAT in the recent GWAS [1].
Activated transcription factor 6 (ATF6 rs2340721) is present in pan-
creatic β cells, adipocytes, and hepatocytes. It becomes activated during
periods of tacrolimus-induced endoplasmic reticulum stress in trans-
plantation, to improve cell survival viamTOR in combating the unfolded
protein response that leads to apoptosis, lipogenesis, and gluconeogen-
esis [15,16]. Although not previously associated with NODAT, this SNP
has been associated with an increased BMI in a renal transplant cohort
[15], pre-diabetes in a Chinese cohort [17], and has been found in tight
linkage disequilibrium (in Caucasians) with rs2070150 which is associ-
ated with type II diabetes in Pima Indians [18]. Mutations in the gene
hepatocyte nuclear factor 4 (HNF4 rs2144908) have been associated
with NODAT [19] and reduced insulin secretion to glucose stimulation
due to progressive β-cell dysfunction, with defects in the GLUT2 trans-
porter and mitochondrial dysfunction in the pathogenesis of maturity
onset of diabetes in the young [20–22]. mTOR has an indirect effect onHNF4α by its regulation of PPARGC1α which co-activates with HNF4α
thus regulating downstream gluconeogenic targets [23,24].
In vivo studies have shown chronic inhibition ofmTORby rapamycin
leads to insulin resistance and lipid dysregulation associatedwith defec-
tive insulin, insulin growth factor signalling, and β-cell toxicity [10,25,
26]. However, there remains controversy over the use of sirolimus and
the development of NODAT with some studies suggesting that its use
is an independent risk factor for NODAT [27] while in others, sirolimus
has been used to improve the metabolic parameters in a small number
of NODAT patients as a substitute for calcineurin inhibitors [28]. Recent
studies have also highlighted the dyslipidaemia, need for more anti-
lipid medication [29], and the requirement for higher steroid dose in a
sub-analysis of the SYMPHONY trial with the use of sirolimus [30] and
thus questions if conversion to sirolimus will improve the cardiovascu-
lar survival outcomes in patients with or at risk of NODAT.
It should be stated that for the number of SNPs tested in this study
compared to the 18 cases of NODAT and 50 non-NODAT control
patients, the power is 60% to identify OR of 2, with 20%minor allele fre-
quency, thus the 5 identiﬁed SNPs in this study requires further valida-
tion in another cohort as the optimal way of conﬁrming these ﬁndings
[31].
4.1. Conclusion
In summary, this study represents a replication study of candidate
SNPs in regard to the risk of developing NODAT following kidney trans-
plantation. It is hypothesis generating into the prevailing mechanisms
of this important complication of transplantation and may even serve
to stratify the risk for individual patients.
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found in online version.
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